
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

September 6, 2013

Date of Report (Date of earliest event reported)

Chimerix, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-35867
(Commission File Number)

33-0903395
(IRS Employer Identification No.)

2505 Meridian Parkway, Suite 340
Durham, NC
(Address of principal executive offices)

27713
(Zip Code)

Registrant's telephone number, including area code: (919) 806-1074

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01 Other Events.

On September 6, 2013, we announced in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference, that Kenneth I. Moch, Chimerix's Chief Executive Officer, will be presenting at two upcoming investor conferences as follows:

- Morgan Stanley Global Healthcare Conference
Kenneth I. Moch, President and CEO of Chimerix, will present on Monday, September 9, 2013 at 1:15 p.m. EDT at the Grand Hyatt New York in New York City.
- Stifel Healthcare Conference 2013
Kenneth I. Moch, President and CEO of Chimerix, will present on Wednesday, September 11, 2013 at 8:00 a.m. EDT at the Four Seasons Hotel in Boston.

The information in this Item 8.01 and the attached Exhibit 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 8.01 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of Chimerix, Inc. dated September 6, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Chimerix, Inc.

Dated: September 9, 2013

By: /s/ Timothy W. Trost
Timothy W. Trost
Senior Vice President, Chief Financial Officer and Corporate Secretary

INDEX TO EXHIBITS

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release of Chimerix, Inc. dated September 6, 2013.



Chimerix to Present at Morgan Stanley and Stifel Healthcare Conferences in September

DURHAM, NC, September 6, 2013 – Chimerix, Inc. (NASDAQ: CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today presentations at the following upcoming investor conferences in September:

- **Morgan Stanley Global Healthcare Conference**

Kenneth I. Moch, President and CEO of Chimerix, will present on Monday, September 9, 2013 at 1:15 p.m. EDT at the Grand Hyatt New York in New York City.

- **Stifel Healthcare Conference 2013**

Kenneth I. Moch, President and CEO of Chimerix, will present on Wednesday, September 11, 2013 at 8:00 a.m. EDT at the Four Seasons Hotel in Boston.

A live audio webcast of each presentation will be available on the Investor Relations section of Chimerix's website at <http://ir.chimerix.com/events.cfm>, where it will be archived for 30 days.

About Chimerix

Chimerix, a biopharmaceutical company based in Durham, NC, is committed to the discovery, development and commercialization of novel, oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need. Chimerix's proprietary lipid technology has given rise to two clinical-stage nucleotide analog lipid-conjugates, CMX001 and CMX157, which have demonstrated the potential for enhanced activity and safety in convenient, orally administered dosing regimens. CMX001 has shown broad-spectrum activity against double-stranded DNA viruses, including herpesviruses, adenoviruses and polyomaviruses. Chimerix's second product candidate, CMX157, an oral nucleotide analog for the treatment of HIV infection, was licensed to Merck in July 2012.

##

CONTACT:

Joseph T. Schepers
Executive Director, Investor Relations
919-287-4125
jschepers@chimerix.com

MEDIA CONTACT:

Tony Plohoros
908-940-0135
tplohoros@6degreespr.com
